Four Steps Forward, One Leap Back on Global Governance of Synthetic Biology
By ETC Group,
ETC Group
| 12. 19. 2016
CANCUN, MEXICO — This week, 196 countries meeting at the 2016 UN Convention on Biodiversity (CBD) Conference of the Parties made progress on the global governance and oversight of synthetic biology. Synthetic biology (syn bio) has become one of the most fiercely debated topics at the Biodiversity Convention, almost 7 years after civil society first brought the need for precaution and regulation of the new set of biotechnologies to this UN body.
During the 13th Conference of the Parties (COP 13) to the CBD, countries agreed to investigate how digital genetic sequences may be used to commit biopiracy and warned against a risky new genetic extinction technology called gene drives. They also agreed on a working definition of synthetic biology (2) and to support an ongoing expert group to move forward international discussions on the topic. However, this progress was undermined by a significant ‘move backwards’ in safety oversight and risk assessment when a key standing expert group expected to issue risk assessment guidelines for synthetic biology was dissolved.
“Syn bio was among the hottest topics on the negotiating table,”...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...
By Pallab Gosh and Gwyndaf Hughes, BBC News | 06.26.2025
Work has begun on a controversial project to create the building blocks of human life from scratch, in what is believed to be a world first.
The research has been taboo until now because of concerns it could lead to...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...